Article
Biochemistry & Molecular Biology
Anabel Gonzalez-Gil, Ryan N. Porell, Steve M. Fernandes, Eila Maenpaa, T. August Li, Tong Li, Philip C. Wong, Kazuhiro Aoki, Michael Tiemeyer, Zaikuan J. Yu, Benjamin C. Orsburn, Namandje N. Bumpus, Russell T. Matthews, Ronald L. Schnaar
Summary: Alzheimer's disease is characterized by misfolded proteins, and microglia play a key role in its development. CD33, an inhibitory microglial receptor, is associated with susceptibility to Alzheimer's disease. The ligand RPTP zeta(S3L) is found to be related to the progression of Alzheimer's disease.
JOURNAL OF BIOLOGICAL CHEMISTRY
(2022)
Article
Allergy
Irina Miralda, Nyssa B. Samanas, Albert J. Seo, Jake S. Foronda, Josie Sachen, Yvonne Hui, Shane D. Morrison, Carole A. Oskeritzian, Adrian M. Piliponsky
Summary: This study demonstrates that Siglec-9 and its ligands play an important role in limiting human mast cell activation in vitro, reducing degranulation, arachidonic acid production, and chemokine release.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
(2023)
Article
Cell Biology
Piper A. Robida, Clayton H. Rische, Netali Ben-Baruch Morgenstern, Rethavathi Janarthanam, Yun Cao, Rebecca A. Krier-Burris, Wouter Korver, Alan Xu, Thuy Luu, Julia Schanin, John Leung, Marc E. Rothenberg, Joshua B. Wechsler, Bradford A. Youngblood, Bruce S. Bochner, Jeremy A. O'Sullivan
Summary: Mast cells are tissue-resident cells that contribute to allergic diseases through excessive or inappropriate cellular activation and degranulation. Siglec-6, a receptor selectively expressed by mast cells, could be a promising target for therapeutic intervention. This study found that Siglec-6 is highly expressed by human mast cells and has a potent inhibitory effect on mast cell activation, making it a potential therapeutic target for mast cell-driven diseases.
Article
Immunology
Jiatao Zhou, Zhihui Xiao, Yanli Zhan, Xuemei Qu, Sisi Mou, Chong Deng, Tianxiang Zhang, Xin Lan, Shengfeng Huang, Yingqiu Li
Summary: A novel immunoreceptor BbLcLRR phosphorylated by Lck was identified in amphioxus, which exerts a phosphorylation-dependent inhibitory role in TCR-mediated T-cell activation, indicating a mechanism for maintaining self-tolerance and homeostasis of the amphioxus immune system.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Allergy
Dubravka Smiljkovic, Harald Herrmann, Irina Sadovnik, Susanne Gamperl, Daniela Berger, Gabriele Stefanzl, Gregor Eisenwort, Gregor Hoermann, Sonja Kopanja, Yulia Dorofeeva, Margarete Focke-Tejkl, Peter Jaksch, Konrad Hoetzenecker, Zsolt Szepfalusi, Rudolf Valenta, Michel Arock, Peter Valent
Summary: Siglec-6 is identified as a surface antigen specifically expressed on human MC and basophils. Its expression is dynamically regulated and varies depending on cell types and activation factors. Understanding the expression changes of Siglec-6 provides insights into the function of MC and basophils in allergic reactions.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
(2023)
Article
Immunology
Wouter Korver, Alan Wong, Simon Gebremeskel, Gian Luca Negri, Julia Schanin, Katherine Chang, John Leung, Zachary Benet, Thuy Luu, Emily C. Brock, Kenneth Luehrsen, Alan Xu, Bradford A. Youngblood
Summary: This study reveals the inhibitory effect of Siglec-8 mAb on MC activity. Siglec-8 regulates Fc epsilon RI-induced phosphorylation events through phosphatase recruitment and interaction with Fc epsilon RI gamma, resulting in global inhibition of MCs.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Aleksandra Vuchkovska, David G. Glanville, Gina M. Scurti, Michael Nishimura, Paula White, Andrew T. Ulijasz, Makio Iwashima
Summary: The study found that Siglec-5 is expressed by most activated T cells and suppresses T cell activation. Overexpression of Siglec-5 inhibits the activation of NFAT and AP-1. GBS beta-protein reduces the production of cytokines and cytolytic molecules by activated T cells in a Siglec-5 dependent manner. Some tumor cells inhibit T cell activation via Siglec-5. These findings suggest that Siglec-5 could serve as a previously unrecognized inhibitory T cell immune checkpoint molecule and blocking Siglec-5 may enhance anti-tumor T cell functions.
Article
Immunology
Yun Cao, Clayton H. Rische, Bruce S. Bochner, Jeremy A. O'Sullivan
Summary: Siglec-8 is a receptor that binds to sialic acid and has different inhibitory activities on eosinophils and mast cells. Binding of Siglec-8 to antibodies induces cell death in primed eosinophils, but inhibits cellular activation in mast cells. Removal of specific sialylated ligands on cell surfaces alters the effects of Siglec-8 and induces mast cell death without cytokine priming.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Biology
Julia Schanin, Wouter Korver, Emily C. Brock, John Leung, Zachary Benet, Thuy Luu, Katherine Chang, Alan Xu, Naomi De Freitas, Kenneth Luehrsen, Michael A. Brehm, Alan Wong, Bradford A. Youngblood
Summary: This study identified an agonistic Siglec-6 mAb that induces inhibition and reduction of mast cells through Fc-mediated interaction. The findings suggest that targeting Siglec-6 with agonistic antibodies may be a potential therapeutic approach for allergic diseases.
COMMUNICATIONS BIOLOGY
(2022)
Review
Oncology
Samanta Jerin, Amanda J. Harvey, Annabelle Lewis
Summary: Protein tyrosine kinase 6 (PTK6) is a biomarker of poor prognosis in breast cancer and has potential significance in colorectal cancer. PTK6 phosphorylates multiple substrates involved in colorectal cancer pathways and is overexpressed in colorectal tumors. Targeting PTK6 in colorectal cancer may enhance sensitivity to chemotherapy.
Article
Hematology
Zhaogong Zhi, Natalie J. Jooss, Yi Sun, Martina Colicchia, Alexandre Slater, Luis A. Moran, Hilaire Yam Fung Cheung, Ying Di, Julie Rayes, Natalie S. Poulter, Steve P. Watson, Asif J. Iqbal
Summary: In this study, Gal-9 was identified as a novel platelet agonist that induces activation through interaction with GPVI and CLEC-2.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
(2022)
Article
Medicine, Research & Experimental
Yin Wu, Darong Yang, Guo-Yun Chen
Summary: This study demonstrates the essential role of Rab1a in embryonic development in mice, with homozygotes dying between E10.5 and E11.5. Rab1a is highly expressed in the small intestine, but its expression levels are low in the brains of embryos.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
(2022)
Article
Oncology
Meeri Kastinen, Paeivi Sirnio, Hanna Elomaa, Maarit Ahtiainen, Sara A. Vayrynen, Karl-Heinz Herzig, Sanna Merilainen, Raila Aro, Reetta Haivala, Tero Rautio, Juha Saarnio, Erkki-Ville Wirta, Olli Helminen, Toni T. Seppala, Teijo Kuopio, Jan Bohm, Anne Tuomisto, Jukka-Pekka Mecklin, Markus J. Makinen, Juha P. Vayrynen
Summary: This study analyzed data from 1413 patients with colorectal cancer and found associations between tumor necrosis percentage and tumor characteristics, immune cell infiltrates, serum cytokine concentrations, as well as prognosis. The results showed that high tumor necrosis percentage is associated with shorter colorectal cancer-specific survival, independent of other factors. Tumor necrosis is therefore considered an important prognostic factor in colorectal cancer.
BRITISH JOURNAL OF CANCER
(2023)
Article
Immunology
Stefanie Westermann, Axel Dietschmann, Daniela Doehler, Kirstin Castiglione, Bruce S. Bochner, David Voehringer, Daniel Radtke
Summary: This study investigated the modulation of activated eosinophils by the transmembrane receptor Siglec-F. It was found that Siglec-F can enhance the secretion of cytokines and chemokines from eosinophils, independent of ITIM phosphorylation. The presence of the cytoplasmic tail of Siglec-F was essential for this effect.
JOURNAL OF IMMUNOLOGY
(2022)
Article
Dentistry, Oral Surgery & Medicine
Xiangqi Liu, Qunxing Li, Ying Zhou, Xinlin He, Juan Fang, Huanzi Lu, Xi Wang, Dikan Wang, Da Ma, Bin Cheng, Guiqing Liao, Zhi Wang
Summary: The study revealed that T-cell expression of TIGIT is elevated in patients with oral squamous cell carcinoma (OSCC) and is associated with T stage and nodal invasion. Additionally, TIGIT-expressing T cells display a dysfunctional and inhibitory phenotype, while TIGIT blockade enhances proliferation ability and cytokine production in CD4(+) and CD8(+) T cells.
Article
Allergy
Daniel Elieh Ali Komi, Frank A. Redegeld
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY
(2020)
Article
Nutrition & Dietetics
Esmaeil Mortaz, Milad Moloudizargari, Adnan Khosravi, Mohammad Hossein Asghari, Mehrnaz Movassaghi, Mohammad Varahram, Mohammad Vaezi, Frank A. Redegeld, Johan Garssen
CLINICAL NUTRITION
(2020)
Letter
Allergy
Karin Hufnagl, Sheriene Moussa Afify, Nina Braun, Stefanie Wagner, Michael Wallner, Michael Hauser, Markus Wiederstein, Gabriele Gadermaier, Sabrina Wildner, Frank A. Redegeld, Bart R. Blokhuis, Gerlinde Hofstetter, Isabella Pali-Schoell, Franziska Roth-Walter, Luis F. Pacios, Erika Jensen-Jarolim
Review
Medicine, General & Internal
Irati Beltran Hernandez, Yingxin Yu, Ferry Ossendorp, Mladen Korbelik, Sabrina Oliveira
JOURNAL OF CLINICAL MEDICINE
(2020)
Article
Allergy
Mehmet Goekkaya, Athanasios Damialis, Thomas Nussbaumer, Isabelle Beck, Nikolaos Bounas-Pyrros, Sebastian Bezold, Marie M. Amisi, Franziska Kolek, Antonia Todorova, Adam Chaker, Lorenz Aglas, Fatima Ferreira, Frank A. Redegeld, Jens O. Brunner, Avidan U. Neumann, Claudia Traidl-Hoffmann, Stefanie Gilles
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
(2020)
Article
Cell Biology
Suzanne Abbring, Bart R. J. Blokhuis, Julie L. Miltenburg, Kiri G. J. Romano Olmedo, Johan Garssen, Frank A. Redegeld, Betty C. A. M. van Esch
Article
Multidisciplinary Sciences
Javier Aguilera-Lizarraga, Morgane Florens, Maria Francesca Viola, Piyush Jain, Lisse Decraecker, Iris Appeltans, Maria Cuende-Estevez, Naomi Fabre, Kim Van Beek, Eluisa Perna, Dafne Balemans, Nathalie Stakenborg, Stavroula Theofanous, Goele Bosmans, Stephanie U. Mondelaers, Gianluca Matteoli, Sales Ibiza Martinez, Cintya Lopez-Lopez, Josue Jaramillo-Polanco, Karel Talavera, Yeranddy A. Alpizar, Thorsten B. Feyerabend, Hans-Reimer Rodewald, Ricard Farre, Frank A. Redegeld, Jiyeon Si, Jeroen Raes, Christine Breynaert, Rik Schrijvers, Cedric Bosteels, Bart N. Lambrecht, Scott D. Boyd, Ramona A. Hoh, Deirdre Cabooter, Maxim Nelis, Patrick Augustijns, Sven Hendrix, Jessica Strid, Raf Bisschops, David E. Reed, Stephen J. Vanner, Alexandre Denadai-Souza, Mira M. Wouters, Guy E. Boeckxstaens
Summary: Research has shown that bacterial infection and toxins can trigger the production of specific dietary-antigen-specific IgE antibodies in mice, leading to increased visceral pain. Additionally, injecting food antigens into the rectosigmoid mucosa of patients with irritable bowel syndrome can induce local oedema and mast cell activation, revealing new possibilities for treating related abdominal pain disorders.
Article
Cell Biology
Marijke Zonneveld, Martijn J. C. van Herwijnen, Marcela M. Fernandez-Gutierrez, Alberta Giovanazzi, Anne Marit de Groot, Marije Kleinjan, Toni M. M. van Capel, Alice J. A. M. Sijts, Leonie S. Taams, Johan Garssen, Esther C. de Jong, Michiel Kleerebezem, Esther N. M. Nolte-'t Hoen, Frank A. Redegeld, Marca H. M. Wauben
Summary: Maternal milk extracellular vesicles play a crucial role in supporting epithelial barrier function and modulating the immune system. Their unique proteome can target key hotspots of signaling networks in various cell types within the gastrointestinal tract.
JOURNAL OF EXTRACELLULAR VESICLES
(2021)
Article
Allergy
Mirelle T. A. Kleuskens, Maria L. Haasnoot, Bart M. Herpers, Marleen T. J. van Ampting, Albert J. Bredenoord, Johan Garssen, Frank A. Redegeld, Betty C. A. M. van Esch
Summary: The study investigated the effects of SCFAs acetate, propionate, and butyrate on the esophageal barrier function in EoE, finding that butyrate and propionate can restore the barrier function of esophageal epithelial cells after inflammatory insult. This suggests that these nutraceuticals may have therapeutic benefits in managing EoE.
Article
Cell Biology
Jing Chen, Esther A. Zaal, Celia R. Berkers, Rob Ruijtenbeek, Johan Garssen, Frank A. Redegeld
Summary: The study demonstrates that pretreating MM cells with DHA/EPA before bortezomib significantly enhances chemosensitivity by decreasing GSH levels and altering metabolism, highlighting the role of GSH degradation in overcoming drug resistance. RNA-seq results suggest the NRF2-ATF3/4-CHAC1 signaling pathway as central in GSH degradation and indicate potential connections to various pathways contributing to the tumor suppressive effect. The findings implicate GSH degradation as a promising therapeutic target in MM and provide new insights into combating bortezomib resistance.
Article
Allergy
Sheriene Moussa Afify, Andreas Regner, Luis F. Pacios, Bart R. Blokhuis, Sebastian A. Jensen, Frank A. Redegeld, Isabella Pali-Schoell, Karin Hufnagl, Rodolfo Bianchini, Sonja Guethoff, Matthias F. Kramer, Alessandro Fiocchi, Zdenek Dvorak, Erika Jensen-Jarolim, Franziska Roth-Walter
Summary: The lozenge formulated with catechin-iron complexes effectively masked IgE binding in milk-allergic children and reduced immune reactivity in mice and allergic subjects. By targeting antigen presenting cells, the lozenge dampened immune activation in a non-specific manner, providing immune resilience against allergic symptoms.
CLINICAL AND EXPERIMENTAL ALLERGY
(2022)
Editorial Material
Allergy
Xiaoli Zhao, Bart. R. J. Blokhuis, Frank. A. Redegeld, Iris Chang, Diane Dunham, Hongbing Chen, Kari Nadeau, Johan Garssen, Leon M. J. Knippels, Astrid Hogenkamp
Article
Pharmacology & Pharmacy
Jing Chen, Rob Ruijtenbeek, Johan Garssen, Frank A. Redegeld
Summary: This study found that ethyl ester-DHA/EPA can induce stronger cytotoxicity in MM cells, even in resistant cells. Pretreating MM cells with ethyl ester-DHA/EPA can enhance the cytotoxicity of bortezomib. Additionally, treatment with ethyl ester-DHA/EPA resulted in increased intracellular ROS levels, reflecting enhanced oxidative stress in treated cells.
EUROPEAN JOURNAL OF PHARMACOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Natasa Vukovic, Samer Halabi, Joan Salvador Russo-Cabrera, Bart Blokhuis, Pedro Berraondo, Frank A. M. Redegeld, Dietmar M. W. Zaiss
Summary: Bispecific antibodies (bsAbs) targeting two different antigens offer a higher level of specificity and improved clinical efficacy in cancer therapy compared to monoclonal antibodies (mAbs). We successfully developed dual tumor-associated antigen-targeting bispecific human IgE antibodies to combine the promising potential of IgE molecules with increased target selectivity. These IgE bsAbs demonstrate potent antibody-dependent cell toxicity and have significant clinical application potential.
JOURNAL OF BIOLOGICAL CHEMISTRY
(2022)
Meeting Abstract
Gastroenterology & Hepatology
Maria Haasnoot, Mirelle Kleuskens, Ingrid Terreehorst, Jaap H. Akkerdaas, Ronald van Ree, Frank A. Redegeld, Betty C. Van Esch, Arjan Bredenoord